Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer
Özet
Breast cancer is a heterogeneous disease and may present with different clinical and biological characteristics. At present, breast cancer is divided into molecular subgroups besides its histopathological classification. Decision for adjuvant chemotherapy is made based on not only histopathological characteristics but also molecular and genomic characteristics using indices, guidelines and calculators in early-stage breast cancer. Making a treatment plan through all these prognostic and predictive methods according to risk categories aims at preventing unnecessary or useless treatments. In this review, an attempt to make a general assessment of prognostic and predictive methods is made which may be used for planning individualized therapy and also the comments of the guidelines used by the oncologists worldwide on these methods. © 2018, Indian Council of Medical Research. All rights reserved.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Esbah, Onur | |
| dc.contributor.author | Oksuzoglu, Berna | |
| dc.date.accessioned | 2026-10-18T20:29:28.709355276Z | |
| dc.date.available | 2026-10-18T20:29:28.709355276Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | Breast cancer is a heterogeneous disease and may present with different clinical and biological characteristics. At present, breast cancer is divided into molecular subgroups besides its histopathological classification. Decision for adjuvant chemotherapy is made based on not only histopathological characteristics but also molecular and genomic characteristics using indices, guidelines and calculators in early-stage breast cancer. Making a treatment plan through all these prognostic and predictive methods according to risk categories aims at preventing unnecessary or useless treatments. In this review, an attempt to make a general assessment of prognostic and predictive methods is made which may be used for planning individualized therapy and also the comments of the guidelines used by the oncologists worldwide on these methods. © 2018, Indian Council of Medical Research. All rights reserved. | |
| dc.identifier.doi | 10.4103/ijmr.ijmr_1354_17 | |
| dc.identifier.endpage | 571 | |
| dc.identifier.issn | 0971-5916 | |
| dc.identifier.issue | Novmeber | |
| dc.identifier.pmcid | PMC5861467 | |
| dc.identifier.pmid | 29512598 | |
| dc.identifier.scopus | 2-s2.0-85043988682 | |
| dc.identifier.startpage | 563 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/14682 | |
| dc.identifier.volume | 146 | |
| dc.identifier.wos | WOS:000426920200004 | |
| dc.language.iso | en | |
| dc.publisher | Indian Council of Medical Research | |
| dc.relation.ispartof | Indian Journal of Medical Research | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Adjuvant chemotherapy | |
| dc.subject | Early-stage breast cancer | |
| dc.subject | Predictive | |
| dc.subject | Prognostic | |
| dc.subject | Breast Neoplasms | |
| dc.subject | Chemotherapy, Adjuvant | |
| dc.subject | Estrogen Receptor alpha | |
| dc.subject | Female | |
| dc.subject | Gene Expression Regulation, Neoplastic | |
| dc.subject | Humans | |
| dc.subject | Ki-67 Antigen | |
| dc.subject | Neoplasm Staging | |
| dc.subject | Precision Medicine | |
| dc.subject | Prognosis | |
| dc.subject | Receptor, ErbB-2 | |
| dc.subject | anastrozole | |
| dc.subject | aromatase inhibitor | |
| dc.subject | epidermal growth factor receptor 2 | |
| dc.subject | Ki 67 antigen | |
| dc.subject | tamoxifen | |
| dc.subject | trastuzumab | |
| dc.subject | tumor marker | |
| dc.subject | urokinase receptor | |
| dc.subject | ERBB2 protein, human | |
| dc.subject | estrogen receptor alpha, human | |
| dc.subject | Article | |
| dc.subject | breast cancer | |
| dc.subject | cancer hormone therapy | |
| dc.subject | cancer prognosis | |
| dc.subject | circulating tumor cell | |
| dc.title | Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 12 | |
| rdl.citation.wos | 9 | |
| rdl.department | Department of Medical Oncology, School of Medicine, Erzincan University, Duzce, Turkey. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
